Poultry Vaccine for Inclusion Body Hepatitis


Researchers at the University of Saskatchewan and the University of Guelph have developed the first live multi-strain fowl adenovirus vaccine to prevent Inclusion Body Hepatitis in broiler chickens.
Inclusion body hepatitis is the most prevalent infectious disease affecting the poultry industry in Canada (Gomis, 2006) and is an emerging problem worldwide. In Canada, the direct costs associated with this disease are estimated to be over $15 million annually. Inclusion body hepatitis is caused by fowl adenovirus (FAdV) and lasts 7-14 days with a mortality rate of 5-30%. FAdV infection affects chickens from 10 days to 6 weeks old.

Advantages and Applications

  • Superior protection of parents and progeny against a range of adenoviral strains, including homologous and heterologous strains,
  • Composed of FAdV-2, FAdV-7, FAdV-8a/8b and/or FAdV11 serotype strains,
  • Efficient and easy delivery routes, including, drinking water systems.


Development Status: Laboratory tests and academic clinical trials completed TRL-6
Patent Status: Patents issued in CA 2,725,435 and US 12,969,444 and US 13,943,990
License Status: Available for licensing


David Hobson, DVM, DVSc, PEng, Manager, Technology Transfer & Entrepreneurship

dhobson@uoguelph.ca, 519-824-4120 Ext. 58859


  • Gomis et. al., Inclusion Body Hepatitis as a Primary Disease in Broilers in Saskatchewan. Canada Avian Diseases, 50(4):550-555 (2006).
  • Ojkic et. al., Genotyping of Canadian isolates of FAdV. Avian Pathol. 37(1): 95-100 (2008b).